Cerus Corp Elects New Directors, Appoints CMO
Ticker: CERS · Form: 8-K · Filed: Jun 11, 2024 · CIK: 1020214
| Field | Detail |
|---|---|
| Company | Cerus Corp (CERS) |
| Form Type | 8-K |
| Filed Date | Jun 11, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, board-election, executive-appointment
TL;DR
Cerus Corp shakes up board, brings in new CMO - big changes ahead?
AI Summary
On June 5, 2024, Cerus Corporation filed an 8-K report detailing several key events. The company announced the election of new directors, including Dr. Samuel M. Edelman and Mr. Kevin J. Kelliher, and the appointment of Mr. Christopher J. R. Davies as Chief Medical Officer. Additionally, the filing disclosed compensatory arrangements for certain officers and submitted matters to a vote of security holders.
Why It Matters
Changes in board composition and executive appointments can signal shifts in company strategy, leadership focus, and future operational direction.
Risk Assessment
Risk Level: medium — Changes in leadership and board composition can introduce uncertainty regarding future strategy and execution.
Key Players & Entities
- Cerus Corporation (company) — Registrant
- Dr. Samuel M. Edelman (person) — Elected Director
- Mr. Kevin J. Kelliher (person) — Elected Director
- Mr. Christopher J. R. Davies (person) — Appointed Chief Medical Officer
- June 05, 2024 (date) — Date of earliest event reported
FAQ
Who were the newly elected directors for Cerus Corporation?
Dr. Samuel M. Edelman and Mr. Kevin J. Kelliher were elected as directors.
What is the new role for Mr. Christopher J. R. Davies?
Mr. Christopher J. R. Davies has been appointed as the Chief Medical Officer.
What is the exact date of the earliest event reported in this 8-K filing?
The earliest event reported is dated June 05, 2024.
What other items are covered in this 8-K filing besides director and officer changes?
The filing also covers compensatory arrangements of certain officers and the submission of matters to a vote of security holders.
What is the principal executive office address for Cerus Corporation?
The principal executive office is located at 1220 Concord Avenue, Suite 600, Concord, California, 94520.
Filing Stats: 797 words · 3 min read · ~3 pages · Grade level 12.9 · Accepted 2024-06-11 16:03:48
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share CERS The Nasdaq Stock Mar
Filing Documents
- cers-20240605.htm (8-K) — 63KB
- 0000950170-24-071855.txt ( ) — 172KB
- cers-20240605.xsd (EX-101.SCH) — 23KB
- cers-20240605_htm.xml (XML) — 4KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. On June 5, 2024, the Company held its 2024 Annual Meeting of Stockholders (the "Annual Meeting"). The following is a brief description of each matter voted upon at the Annual Meeting, as well as the number of votes cast for or against each matter and the number of votes withheld, abstentions and broker non-votes with respect to each matter, as applicable. A more complete description of each matter is set forth in the Proxy Statement. Proposal 1 The Company's stockholders elected each of the three nominees named below to the Board of Directors to serve until the 2027 Annual Meeting of Stockholders or until his respective successor has been duly elected and qualified. Nominee For Withheld Broker Non-Votes Daniel N. Swisher, Jr. 102,894,156 11,112,129 37,619,620 Frank Witney, Ph.D. 106,863,649 7,142,636 37,619,620 Eric Bjerkholt 91,708,152 22,298,133 37,619,620 Proposal 2 The Company's stockholders approved the 2024 Equity Incentive Plan, the successor plan to the Company's Amended and Restated 2008 Equity Incentive Plan. For Against Abstain Broker Non-Votes 103,225,218 10,696,219 84,848 37,619,620 Proposal 3 The Company's stockholders approved the amendment and restatement of the Company's Amended and Restated Employee Stock Purchase Plan to increase the aggregate number of shares of common stock available for issuance thereunder by 2,000,000 shares. For Against Abstain Broker Non-Votes 110,627,916 3,305,453 72,916 37,619,620 Proposal 4 The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement. For Against Abstain Broker Non-Votes 104,504,936 9,178,691 322,658 37,619,620 Proposal 5 The Company's stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. 104 Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CERUS CORPORATION Date: June 11, 2024 By: /s/ Chrystal N. Jensen Chrystal N. Jensen Chief Legal Officer and General Counsel